Cord blood transplantation (CBT) is an alternative source of allo-SCT in patients lacking a suitable identical sibling or a wellmatched unrelated donor. Although CBT may have the advantage of less-stringent HLA matching, it is limited by the number of cells leading to increased risk of nonengraftment. A strategy has been pioneered by the Minneapolis's group in adults to combine two units from two different donors. 1, 2 This strategy allows sustained engraftment but has been claimed to be associated with increased risk of GVHD. 3 Furthermore, in the vast majority of such double CBT, only one unit accounts for long-term engraftment (reviewed by Eldjerou et al.
4
). However, initial engraftment usually relies on both units and it is currently unknown which of the 2 units, the dominant unit, or the 'loser' one, triggers GVHD in target organs. To address this question, we developed, in two patients, HLA allele-specific quantitative PCR and assessed in situ chimerism after laser micro dissection of mononuclear cells that infiltrate the gut at onset of acute GVHD.
We took advantage of the frequent HLA mismatches in CBT to design a multiplex quantitative PCR with sets of primers and probes specific for each UCB HLA polymorphism and for the control albumin gene. Using lymphoblastoid cell lines obtained by specific immortalization of B lymphocytes from the recipient and each unit, we verified the lack of interaction between the different primers and probes, as well as the absence of unspecific amplification with other HLA sequences; and finally, we optimized primer and probe concentrations for each to increase PCR sensitivity to be able to detect 1 in 500 cells (see Table 1 ). Lymphocytes were dissected from biopsy slide with the Laser Pressure Catapulting system (PALM, Bernreid, Germany) as previously described. 5 This study has been approved by the review board of the Hospital Saint Louis, and biopsies were performed for clinical purposes.
The first patient was a 15-year-old boy transplanted for Fanconi anemia. On day 30 post transplantation, the patient presented diarrhea. The infiltrate in duodenal samples showed the presence of the engrafted UCB unit (unit 2), with no amplification for unit 1. The second patient was transplanted for CML. Peripheral blood chimerism analysis showed the dominance of UCB unit 1 after transplantation. Diarrhea occurred 5 months after transplantation. We choose to amplify specifically unit 1 with HLA C mismatch and unit 2 with DRB1 mismatch, and here again we demonstrated the presence of cells from the engrafted unit among infiltrate in digestive biopsies.
The technique we used here is time consuming, expensive and needs to design and develop patient-specific quantitative-PCR. Indeed, we failed to design or have a reproducible, meaningful amplification in the setting of four additional cases. Furthermore, due to the sensitivity limit of the method we used few cells of the other (losing) unit that could have been missed. This, therefore, cannot be considered for routine usage. Conclusions are limited to the number of patients studied. However, it clearly demonstrates, in these two cases, that the dominant unit is also the one triggering acute GVHD. 
